Trial Profile
An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 04 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Feb 2020 Planned End Date changed from 31 Dec 2019 to 4 Apr 2020.
- 04 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 4 Apr 2020.